miRNA targets DNA for Regulation

Regulus Gains Orphan Drug Designation for microRNA Treatment

A recent press release by the company Regulus Therapeutics highlights their newest orphan drug RG-012 – a microRNA treatment designed to help patients with Alport Syndrome, a life-threatening genetic kidney disease that impacts the body’s ability to create a specific type of collagen highly expressed in the kidney and essential to normal kidney structure. The release neglects to mention is that this …